Tranzyme Pharma announced positive results from its Phase 2 study of TZP-101 for the treatment of gastroparesis in patients with diabetes mellitus (DM). This study was a double-blind, placebo-controlled trial in 76 patients with either type 1 or 2 DM and a confirmed diagnosis of gastroparesis (by presence of both chronic symptoms and objective demonstration of delayed gastric emptying). During treatment and at a 30-day follow-up visit, efficacy was evaluated by symptom improvement as assessed by the Gastroparesis Cardinal Symptom Index (GCSI). Additionally, meal-related Gastroparesis Symptom Assessment (GSA) and Clinician Rated Symptom Assessment (CRSA) scores were collected for the study. TZP-101 was found to be safe and effective in improving multiple symptoms associated with gastroparesis.
TZP-101 is an intravenous ghrelin agonist in clinical development for the treatment of postoperative ileus (POI) and gastroparesis in acute care settings.
For more information call (919) 313-4760 or visit www.tranzyme.com.